Warning: The NCBI web site requires JavaScript to function. more...
Progress in osteoporosis and fracture prevention: focus on postmenopausal women.
Saag KG, Geusens P.
Arthritis Res Ther. 2009;11(5):251. Epub 2009 Oct 14. Review.
Related citations
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
Health Technol Assess. 2005 Jun;9(22):1-160. Review.
Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
Miller RG.
Geriatrics. 2006 Jan;61(1):24-30. Review.
Strategies for treatment to prevent fragility fractures in postmenopausal women.
Geusens P.
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):727-40. Review.
Osteodensitometry in healthy postmenopausal women.
[No authors listed]
Prescrire Int. 2008 Apr;17(94):68-72.
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause. 2010 Jan-Feb;17(1):25-54; quiz 55-6.
Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
Siris ES, Baim S, Nattiv A.
Postgrad Med. 2010 Jan;122(1):82-90. Review.
Preventing osteoporosis-related fractures: an overview.
Gass M, Dawson-Hughes B.
Am J Med. 2006 Apr;119(4 Suppl 1):S3-S11. Review.
[Therapeutic concepts in the treatment of postmenopausal osteoporosis].
Leidig-Bruckner G, Ziegler R.
Ther Umsch. 1994 Nov;51(11):737-47. German.
Review of postmenopausal osteoporosis pharmacotherapy.
Mayes SL.
Nutr Clin Pract. 2007 Jun;22(3):276-85. Review.
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group.
Osteoporos Int. 2008 Oct;19(10):1395-408. Epub 2008 Aug 28. Erratum in: Osteoporos Int. 2009 Mar;20(3):499-502.
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP.
Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.
Recognition of women at risk for fracture and intervention with fast-acting therapies.
Derman R.
Int J Fertil Womens Med. 2006 Jul-Aug;51(4):183-90. Review.
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
Sickels JM, Nip CS.
Ann Pharmacother. 2002 Apr;36(4):664-70. Review.
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB.
Arch Intern Med. 1997 Dec 8-22;157(22):2617-24.
Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis.
Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB.
Pharmacotherapy. 2006 Jan;26(1):104-14. Review.
Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
Marcus R, Wong M, Heath H 3rd, Stock JL.
Endocr Rev. 2002 Feb;23(1):16-37. Review.
Current approach to fracture prevention in postmenopausal osteoporosis.
Kaplan B, Hirsch M.
Clin Exp Obstet Gynecol. 2004;31(4):251-5. Review.
Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis.
de Villiers TJ.
Climacteric. 2010 Jun;13(3):210-8. Review.
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.
JAMA. 1999 Oct 13;282(14):1344-52.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on